Evidence map›Paper›PMID 36950028›Full record

ArticleCanadian journal of kidney health and disease2023

Determining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol.

Kevin Yau, Omosomi Enilama, Adeera Levin, Marc G Romney, Joel Singer, Peter Blake, Jeffrey Perl, Jerome A Leis, Robert Kozak, Hubert Tsui and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of kidney health and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 10 institutions in 1 country.

Kevin YauDivision of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.ORCID https://orcid.org/0000-0001-8653-6778
Omosomi EnilamaExperimental Medicine, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Adeera LevinDivision of Nephrology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Marc G RomneyDepartment of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care, Vancouver, BC, Canada.
Joel SingerSchool of Population and Public Health, The University of British Columbia, Vancouver, BC, Canada.
Peter BlakeOntario Renal Network, Toronto, ON, Canada.
Jeffrey PerlDivision of Nephrology, Department of Medicine, Unity Health Toronto, ON, Canada.
Jerome A LeisDivision of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Robert KozakDepartment of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.
Hubert TsuiDepartment of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.
Shelly BolotinPublic Health Ontario, Toronto, ON, Canada.
Vanessa TranPublic Health Ontario, Toronto, ON, Canada.
Christopher T ChanDivision of Nephrology, Department of Medicine, University Health Network, Toronto, ON, Canada.
Paul TamDivision of Nephrology, Scarborough Health Network, Toronto, ON, Canada.
Miten DhruveDivision of Nephrology, Michael Garron Hospital, Toronto, ON, Canada.
Christopher KandelDivision of Infectious Diseases, Michael Garron Hospital, Toronto, ON, Canada.
Jose Estrada-CodecidoDivision of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Tyler BrownDivision of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Aswani SiwakotiDivision of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Kento T AbeDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Queenie HuLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
Karen ColwillLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
Anne-Claude GingrasDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Matthew J OliverDivision of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Michelle A HladunewichDivision of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.ORCID https://orcid.org/0000-0001-9227-4292
Sunnybrook Health Science Centre · CAMount Sinai Hospital · CAUniversity of Toronto · CAUniversity of British Columbia · CAToronto East General Hospital · CALondon Health Sciences Centre · CAProvidence Health Care · CAThe Scarborough Hospital · CAUnity Health TorontoUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: People living with chronic kidney disease (CKD) have been disproportionately affected by the coronavirus disease 2019 (COVID-19) pandemic, including higher rates of infection, hospitalization, and death. Data on responsiveness to COVID-19 vaccination strategies and immunogenicity are limited, yet required to inform vaccination strategies in this at-risk population. Objective: The objective of this study is to characterize the longitudinal serologic response to COVID-19 vaccination. Design: This is a prospective observational cohort study. Setting: Participating outpatient kidney programs within Ontario and British Columbia. Patients: Up to 2500 participants with CKD G3b-5D receiving COVID-19 vaccination, including participants receiving dialysis and kidney transplant recipients (CKD G1T-5T). Measurements: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG antibodies (anti-spike, anti-receptor binding domain, anti-nucleocapsid) will be detected by ELISA (enzyme-linked immunosorbent assay) from serum or dried blood spot testing. In a subset of participants, neutralizing antibodies against novel variants of concern will be evaluated. Peripheral blood mononuclear cells will be collected for exploratory immune profiling of SARS-CoV-2 specific cellular immunity. Methods: Participants will be recruited prior to or following any COVID-19 vaccine dose and have blood sampled for serological testing at multiple timepoints: 1, 3, 6, 9, and 12 months post vaccination. When possible, samples will be collected prior to a dose or booster. Participants will remain in the study for at least 1 year following their last COVID-19 vaccine dose. Strengths and limitations: The adaptive design of this study allows for planned modification based on emerging evidence or rapid changes in public health policy surrounding vaccination. Limitations include incomplete earlier timepoints for blood collection due to rapid vaccination of the population. Conclusions: This large multicenter serologic study of participants living with kidney disease will generate data on the kinetics of SARS-CoV-2 immune response to vaccination across the spectrum of CKD, providing insights into the amplitude and duration of immunity conferred by COVID-19 vaccination and allowing for characterization of factors associated with immune response. The results of this study may be used to inform immunization guidelines and public health recommendations for the 4 million Canadians living with CKD.

Indexed as

chronic kidney diseaseCOVID-19dialysisserologyvaccine

Identifiers

PMID36950028
PMCPMC10028441
OpenAlexW4328022739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.